

Kirsten C Morley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2811024/publications.pdf>

Version: 2024-02-01

86
papers

2,482
citations

201658

27
h-index

223791

46
g-index

89
all docs

89
docs citations

89
times ranked

2463
citing authors

#	ARTICLE	IF	CITATIONS
1	Naltrexone versus acamprosate in the treatment of alcohol dependence: a multicentre, randomized, double-blind, placebo-controlled trial. <i>Addiction</i> , 2006, 101, 1451-1462.	3.3	143
2	Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2018, 28, 795-806.	0.7	135
3	Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine (‘‘Ecstasy’’). <i>European Journal of Pharmacology</i> , 2001, 433, 91-99.	3.5	120
4	(Δ)-3,4-Methylenedioxymethamphetamine (MDMA, ‘‘Ecstasy’’™) increases social interaction in rats. <i>European Journal of Pharmacology</i> , 2000, 408, 41-49.	3.5	98
5	Psychosocial interventions for people with both severe mental illness and substance misuse. <i>The Cochrane Library</i> , 2013, , CD001088.	2.8	97
6	Pharmacotherapeutic agents in the treatment of methamphetamine dependence. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 563-578.	4.1	97
7	Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. <i>Lancet Psychiatry</i> , 2018, 5, 957-960.	7.4	94
8	Psychosocial Interventions for People With Both Severe Mental Illness and Substance Misuse. <i>Schizophrenia Bulletin</i> , 2014, 40, 18-20.	4.3	93
9	Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion. <i>European Journal of Pharmacology</i> , 2002, 446, 89-96.	3.5	88
10	Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. <i>British Journal of Psychiatry</i> , 2018, 212, 362-369.	2.8	87
11	Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety. <i>Alcohol and Alcoholism</i> , 2014, 49, 654-660.	1.6	82
12	Increased anxiety and ‘‘depressive’’ symptoms months after MDMA (‘‘ecstasy’’) in rats: drug-induced hyperthermia does not predict long-term outcomes. <i>Psychopharmacology</i> , 2003, 168, 465-474.	3.1	79
13	Heat increases 3,4-methylenedioxymethamphetamine self-administration and social effects in rats. <i>European Journal of Pharmacology</i> , 2003, 482, 339-341.	3.5	68
14	Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 648-657.	4.8	61
15	Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?. <i>Addiction</i> , 2008, 103, 953-959.	3.3	57
16	Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA (‘‘Ecstasy’’) in rats. <i>Neuropharmacology</i> , 2004, 46, 954-965.	4.1	52
17	The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective. <i>Frontiers in Psychiatry</i> , 2018, 9, 708.	2.6	47
18	Systematic Reviews of Mindfulness and Acceptance and Commitment Therapy for Alcohol Use Disorder: Should we be using Third Wave Therapies?. <i>Alcohol and Alcoholism</i> , 2019, 54, 159-166.	1.6	44

#	ARTICLE	IF	CITATIONS
19	Alcohol use disorder and circulating cytokines: A systematic review and meta-analysis. <i>Brain, Behavior, and Immunity</i> , 2020, 89, 501-512.	4.1	44
20	The consequences of beer consumption in rats: acute anxiolytic and ataxic effects and withdrawal-induced anxiety. <i>Psychopharmacology</i> , 2003, 166, 51-60.	3.1	41
21	Psychosocial interventions for people with both severe mental illness and substance misuse. <i>The Cochrane Library</i> , 2019, 2019, CD001088.	2.8	40
22	The role of clinical champions in facilitating the use of evidence-based practice in drug and alcohol and mental health settings: A systematic review. <i>Implementation Research and Practice</i> , 2020, 1, 263348952095907.	1.9	35
23	National trends in alcohol pharmacotherapy: Findings from an Australian claims database. <i>Drug and Alcohol Dependence</i> , 2016, 166, 254-257.	3.2	34
24	New Australian guidelines for the treatment of alcohol problems: an overview of recommendations. <i>Medical Journal of Australia</i> , 2021, 215, S3-S32.	1.7	34
25	Issues with recruitment to randomised controlled trials in the drug and alcohol field: a literature review and Australian case study. <i>Drug and Alcohol Review</i> , 2008, 27, 115-122.	2.1	33
26	Some new directions for research on psychological interventions for comorbid anxiety and substance use disorders. <i>Drug and Alcohol Review</i> , 2010, 29, 518-524.	2.1	31
27	Expectancy in Double-Blind Placebo-Controlled Trials: An Example from Alcohol Dependence. <i>Psychotherapy and Psychosomatics</i> , 2009, 78, 167-171.	8.8	29
28	Is Specialized Integrated Treatment for Comorbid Anxiety, Depression and Alcohol Dependence Better than Treatment as Usual in a Public Hospital Setting?. <i>Alcohol and Alcoholism</i> , 2016, 51, 402-409.	1.6	29
29	The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): Study protocol for a randomised controlled trial. <i>Contemporary Clinical Trials</i> , 2013, 36, 348-355.	1.8	27
30	The efficacy of an opportunistic cognitive behavioral intervention package (OCB) on substance use and comorbid suicide risk: A multisite randomized controlled trial.. <i>Journal of Consulting and Clinical Psychology</i> , 2014, 82, 130-140.	2.0	27
31	Learning and generalization from reward and punishment in opioid addiction. <i>Behavioural Brain Research</i> , 2017, 317, 122-131.	2.2	27
32	Biased and less sensitive: A gamified approach to delay discounting in heroin addiction. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2018, 40, 139-150.	1.3	27
33	A Mobile Text Message Intervention to Reduce Repeat Suicidal Episodes: Design and Development of Reconnecting After a Suicide Attempt (RAFT). <i>JMIR Mental Health</i> , 2017, 4, e56.	3.3	27
34	Cue Exposure Therapy for Alcohol Use Disorders: What Can Be Learned from Exposure Therapy for Anxiety Disorders?. <i>Substance Use and Misuse</i> , 2019, 54, 2053-2063.	1.4	25
35	N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: Rationale for further research. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 667-675.	4.1	20
36	A systematic review of evidence-based practice implementation in drug and alcohol settings: applying the consolidated framework for implementation research framework. <i>Implementation Science</i> , 2021, 16, 22.	6.9	20

#	ARTICLE	IF	CITATIONS
37	Moderation of baclofen response by a GABA _B receptor polymorphism: results from the BacALD randomized controlled trial. <i>Addiction</i> , 2018, 113, 2205-2213.	3.3	19
38	Drinking risk varies within and between Australian Aboriginal and Torres Strait Islander samples: a meta-analysis to identify sources of heterogeneity. <i>Addiction</i> , 2020, 115, 1817-1830.	3.3	19
39	Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. <i>Psychopharmacology</i> , 2021, 238, 1291-1302.	3.1	19
40	New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1291-1303.	1.8	18
41	Preexposure to MDMA (‘Ecstasy’) delays acquisition but facilitates MDMA-induced reinstatement of amphetamine self-administration behavior in rats. <i>Pharmacology Biochemistry and Behavior</i> , 2004, 79, 331-342.	2.9	17
42	Socioeconomic and geographic disparities in access to pharmacotherapy for alcohol dependence. <i>Journal of Substance Abuse Treatment</i> , 2017, 74, 23-25.	2.8	17
43	Alcohol use disorders in Australia. <i>Internal Medicine Journal</i> , 2016, 46, 1259-1268.	0.8	16
44	Insomnia and excessive daytime sleepiness in women and men receiving methadone and buprenorphine maintenance treatment. <i>Substance Use and Misuse</i> , 2019, 54, 1589-1598.	1.4	14
45	Translating Evidence-Based Practice for Managing Comorbid Substance Use and Mental Illness Using a Multimodal Training Package. <i>Journal of Dual Diagnosis</i> , 2018, 14, 111-119.	1.2	13
46	Implementation of evidence-based practice for alcohol and substance use disorders: protocol for systematic review. <i>Systematic Reviews</i> , 2020, 9, 25.	5.3	13
47	Integrated care for comorbid alcohol dependence and anxiety and/or depressive disorder: study protocol for an assessor-blind, randomized controlled trial. <i>Addiction Science & Clinical Practice</i> , 2013, 8, 19.	2.6	11
48	Executive Functioning Moderates Responses to Appetitive Cues: A Study in Severe Alcohol Use Disorder and Alcoholic Liver Disease. <i>Alcohol and Alcoholism</i> , 2019, 54, 38-46.	1.6	11
49	Prevalence and Risk Factors of Emergency Department Presentations with Methamphetamine Intoxication or Dependence: A Systematic Review and Meta-analysis. <i>Issues in Mental Health Nursing</i> , 2019, 40, 567-578.	1.2	10
50	A Review of Baclofen Overdoses in Australia: Calls to a Poisons Information Centre and a Case Series. <i>Alcohol and Alcoholism</i> , 2019, 54, 73-78.	1.6	10
51	High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: Preliminary findings from a pharmaco-fMRI study. <i>European Neuropsychopharmacology</i> , 2021, 46, 28-36.	0.7	10
52	Sample bias from different recruitment strategies in a randomised controlled trial for alcohol dependence. <i>Drug and Alcohol Review</i> , 2009, 28, 222-229.	2.1	9
53	Clinical Predictors of Outcome from an Australian Pharmacological Relapse Prevention Trial. <i>Alcohol and Alcoholism</i> , 2010, 45, 520-526.	1.6	9
54	Neurometabolite Levels in Alcohol Use Disorder Patients During Baclofen Treatment and Prediction of Relapse to Heavy Drinking. <i>Frontiers in Psychiatry</i> , 2018, 9, 412.	2.6	9

#	ARTICLE	IF	CITATIONS
55	Clinical Predictors of Response to Baclofen in the Treatment of Alcohol use Disorder: Results from the BacALD Trial. <i>Alcohol and Alcoholism</i> , 2019, 54, 272-278.	1.6	9
56	Evidence based models of care for the treatment of alcohol use disorder in primary health care settings: a systematic review. <i>BMC Family Practice</i> , 2020, 21, 260.	2.9	9
57	Intolerance of uncertainty and conditioned place preference in opioid addiction. <i>PeerJ</i> , 2018, 6, e4775.	2.0	9
58	Pharmacotherapy for Alcohol Use Disorder in the Context of Liver Disease. <i>Current Addiction Reports</i> , 2018, 5, 287-296.	3.4	7
59	Brain N-Acetyl Aspartate and associations with cognitive impairment in alcohol dependent patients. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2020, 42, 111-117.	1.3	7
60	Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. <i>Human Psychopharmacology</i> , 2020, 35, e2722.	1.5	7
61	Psychosocial Interventions for Reducing Suicidal Behaviour and Alcohol Consumption in Patients With Alcohol Problems: A Systematic Review of Randomized Controlled Trials. <i>Alcohol and Alcoholism</i> , 2021, 56, 17-27.	1.6	7
62	A Content Analysis of Reddit Users' Perspectives on Reasons for not Following Through with a Suicide Attempt. <i>Cyberpsychology, Behavior, and Social Networking</i> , 2021, 24, 642-647.	3.9	7
63	The role of clinical supervision in implementing evidence-based practice for managing comorbidity. <i>Clinical Supervisor, The</i> , 2021, 40, 158-177.	1.7	7
64	Brain GABA levels are reduced in alcoholic liver disease: A proton magnetic resonance spectroscopy study. <i>Addiction Biology</i> , 2020, 25, e12702.	2.6	6
65	Implementation of a Multi-Modal Training Program for the Management of Comorbid Mental Disorders in Drug and Alcohol Settings: Pathways to Comorbidity Care (PCC). <i>Journal of Dual Diagnosis</i> , 2021, 17, 304-312.	1.2	6
66	GABAB Receptors and Alcohol Use Disorders: Clinical Studies. <i>Current Topics in Behavioral Neurosciences</i> , 2020, , 195-212.	1.7	6
67	Baclofen Response in Alcohol Dependent Patients Concurrently Receiving Antidepressants: Secondary Analysis From the BacALD Study. <i>Frontiers in Psychiatry</i> , 2018, 9, 576.	2.6	5
68	Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study). <i>Trials</i> , 2018, 19, 443.	1.6	5
69	The impact of alcohol pharmacotherapies on public health in Australia is limited by low prescribing rates. <i>Public Health Research and Practice</i> , 2016, 26, .	1.5	5
70	Genetic Polymorphisms on OPRM1, DRD2, DRD4, and COMT in Young Adults: Lack of Association With Alcohol Consumption. <i>Frontiers in Psychiatry</i> , 2020, 11, 549429.	2.6	4
71	Commentary on Donoghue: Low prescribing rates of pharmacotherapy for alcohol use disorder limit potential public health impact. <i>Addiction</i> , 2021, 116, 3027-3028.	3.3	4
72	Barriers and Facilitators to the Implementation of the Pathways to Comorbidity Care (PCC) Training Package for the Management of Comorbid Mental Disorders in Drug and Alcohol Settings. , 2021, 1, .		4

#	ARTICLE	IF	CITATIONS
73	Sex as a Potential Moderator for Baclofen Response in the Treatment of Alcohol Dependence. <i>Frontiers in Global Women S Health</i> , 2022, 3, 807269.	2.3	4
74	Pericyazine in the treatment of cannabis dependence in general practice: a naturalistic pilot trial. <i>Substance Abuse and Rehabilitation</i> , 2012, 3, 43.	4.8	3
75	Reward and punishment-based compound cue learning and generalization in opiate dependency. <i>Experimental Brain Research</i> , 2017, 235, 3153-3162.	1.5	3
76	A pilot study of escape, avoidance, and approach behaviors in treated alcohol-dependent males. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2019, 41, 601-614.	1.3	3
77	Evidence-based models of care for the treatment of alcohol use disorder in primary health care settings: protocol for systematic review. <i>Systematic Reviews</i> , 2019, 8, 275.	5.3	3
78	Treatment of alcohol problems: current status and future directions. <i>Medical Journal of Australia</i> , 2021, 215, 315-316.	1.7	3
79	The evaluation of the role of technology in the pathways to comorbidity care implementation project to improve management of comorbid substance use and mental disorders. <i>Journal of Multimorbidity and Comorbidity</i> , 2022, 12, 263355652210969.	2.2	3
80	Characteristics of Suicide Attempters and Ideators in a Clinical Sample of Substance Users. <i>Substance Use and Misuse</i> , 2018, 53, 1811-1818.	1.4	2
81	Assessing the validity of the Wechsler Adult Intelligence Scale (WAIS-IV) in predicting completion in a long-term residential rehabilitation for substance use problems. <i>Applied Neuropsychology Adult</i> , 2021, , 1-6.	1.2	2
82	A pilot study of a text message and online brief contact intervention following self-harm or a suicide attempt: A mixed methods evaluation. <i>General Hospital Psychiatry</i> , 2022, 76, 1-2.	2.4	2
83	Online interventions for people hospitalized for deliberate self-harm and problematic alcohol use: Lessons learned from the iiAIM trial. <i>Bulletin of the Menninger Clinic</i> , 2021, 85, 123-142.	0.6	1
84	Daily experiences of hangover severity and food consumption in young adults. <i>British Journal of Health Psychology</i> , 2022, 27, 468-483.	3.5	1
85	Psychostimulant-related health service demand in an inner-city hospital, 2012â€“2015. <i>Public Health Research and Practice</i> , 2018, 28, .	1.5	1
86	Are bottle shops using Twitter to increase advertising or encourage drinking during COVIDâ€“19?. <i>Australian and New Zealand Journal of Public Health</i> , 2021, 45, 391-393.	1.8	0